Clinical trial services group Ergomed Plc (LON:ERGO) has made its first cross-sale following the acquisition of German companies O+P and GASD in June.
The contract is worth €1.5mln and covers six countries.
Miroslav Reljanovic, Ergomed’s chief executive, said he was delighted with the deal, which was with an existing customer of O+P and GASD.
“The significantly broadened suite of Ergomed services provided to this customer validates the rationale behind our recent acquisitions of these German businesses.
“Offering a comprehensive range of clinical trial solutions will enable us to grow our existing business as well as attract customers from new markets,” he said, adding more bolt-on deal are now likely.